Compare Neurocrine Biosciences Inc (NBIX) vs Raytheon Technologies Corp (RTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Raytheon Technologies Corp — how do they compare? Neurocrine Biosciences Inc trades at $141.13 (market cap $14.36B), while Raytheon Technologies Corp trades at $185.1 (market cap $248.42B). The key difference: Raytheon Technologies Corp is far larger — about 17.3× Neurocrine Biosciences Inc's market cap, and Raytheon Technologies Corp pays a 1.58% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Raytheon Technologies Corp for 78 Days on average.
| NBIX | RTX | |
|---|---|---|
Market Cap | $14.36B | $248.42B |
Volume | 1,237,180 | 4,380,368 |
Sector | Health | Industrials |
52-Week High | $185.50 | $225.49 |
52-Week Low | $123.10 | $157.00 |
Typical Hold Time | 23 Days | 78 Days |
Enterprise Value | $14.37B | $278.97B |
Dividend Yield | — | 1.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
RTX trades at $180.26, down 1.65% today, amid a bearish technical signal but strong fundamental performance. The company reported three consecutive quarterly earnings beats, with Q3 2026 EPS expected at $1.77. Revenue grew to $88.6B in 2025, with net income margin improving to 7.59%. Analyst consensus remains strongly bullish with a $236.27 price target and 65% buy ratings, supported by a $289B backlog and defense sector tailwinds.
The outlook for RTX is positive given robust defense spending, earnings momentum, and analyst confidence. Risks include execution on large contracts, debt levels, and geopolitical uncertainties. The stock offers growth potential with a 30% upside to consensus target, but investors should monitor quarterly execution and defense budget developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →
